Overview
- An ASCO abstract reported that preclinical pancreatic cancer models with KRAS G12C and G12D mutations showed synergistic tumor killing when AKTX-101 was combined with the KRAS inhibitor adagrasib.
- Akari says the effect stems from a novel payload called PH1 that modulates the RNA spliceosome to mark pre‑mRNA, including mutant KRAS transcripts, for degradation.
- The company contrasted its results with first‑generation TROP2 ADCs that reportedly produced antagonism with adagrasib, highlighting how payload chemistry can change combination outcomes.
- The ASCO disclosure triggered an about 120% after‑hours share surge, but Akari remains a micro‑cap with roughly $5.8 million market value, no human efficacy data, limited resources, and continued execution and regulatory risk.
- Akari has started IND‑enabling studies and aims to begin a Phase 1 first‑in‑human trial around mid‑2027 while also advancing an earlier AKTX‑102 program, though clinical translation of these preclinical findings is uncertain.